Tempus AI (TEM) Valuation Check After Daiichi Sankyo Oncology Collaboration Announcement

Tempus AI’s oncology collaboration puts its AI platform in focus

Tempus AI (TEM) drew fresh attention after announcing a collaboration with Daiichi Sankyo to apply its PRISM2 multimodal foundation model and real world oncology data to a novel antibody drug conjugate program.

See our latest analysis for Tempus AI.

The Daiichi Sankyo collaboration arrives after a volatile stretch for the stock, with a 1-day share price return of 6.7% lifting Tempus AI to US$45.22. However, a weaker 90-day share price return of a 23.4% decline and a 1-year total shareholder return of a 4.2% decline point to fading momentum overall.

If you are tracking how AI in healthcare is being priced by the market, it can be useful to compare Tempus AI with other names using our 34 healthcare AI stocks

With Tempus AI posting revenue of US$1.27b, a net loss of US$245.03m and trading at a sizeable discount to analyst targets, the key question is whether the recent weakness signals mispricing or if markets are already accounting for future growth.

Most Popular Narrative: 42% Undervalued

Tempus AI’s most followed valuation narrative points to a fair value of $77.93 per share versus the last close at $45.22. This creates a wide gap investors may want to understand.

The analysts have a consensus price target of $77.93 for Tempus AI based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of $58.0.

Read the complete narrative.

Want to see what is sitting behind that wide spread in price targets? The narrative focuses on revenue compounding and a potential step change in future margins. This raises the question of how those moving parts combine into that fair value line.

Result: Fair Value of $77.93 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are clear watchpoints, including pressure from larger diagnostics and AI rivals, as well as ongoing reimbursement uncertainty that could limit how quickly Tempus turns its platform into cash flow.

Find out about the key risks to this Tempus AI narrative.

Another Angle On Tempus AI’s Valuation

The earlier view leans on analyst targets and future earnings assumptions, which suggest Tempus AI could be undervalued. The market today, though, is pricing the stock at a P/S of 6.4x versus 2.7x for the US Life Sciences industry and an estimated fair ratio of 7.1x. This leaves you to weigh how much valuation risk that premium really carries if sentiment shifts.

To see how this pricing gap looks through a single ratio lens, and how it could change if the market moves closer to the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, and both risks and rewards in play, it makes sense to move fast and test the assumptions against hard numbers yourself using 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Tempus AI has your attention, do not stop there. Broaden your watchlist with a few focused stock ideas that match different investing goals.

• Target resilient income by scanning companies with steady payouts and higher yields using the 12 dividend fortresses.
• Hunt for potential bargains by filtering companies that pair quality fundamentals with attractive pricing through the 58 high quality undervalued stocks.
• Prioritise capital protection by zeroing in on companies with stronger balance sheets and lower risk profiles via the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com